A Phase 1/2 clinical trial of the X-linked retinitis pigmentosa gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.

Trial Profile

A Phase 1/2 clinical trial of the X-linked retinitis pigmentosa gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs X-linked-retinitis-pigmentosa-gene-therapy-Applied-Genetic-Technologies-Corporation (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Sep 2017 According to an Applied Genetic Technologies Corporation media release, the company is currently conducting site initiation activities at four clinical sites and plans to initiate a clinical study in the United States in the first quarter of 2018.
    • 13 Sep 2017 According to an Applied Genetic Technologies Corporation media release, the company has filed an IND with the FDA to support the initiation of this phase I/II study in the early Aug 2017.
    • 17 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top